John Libbey Eurotext

Hépato-Gastro & Oncologie Digestive


Everolimus and sunitinib in digestive neuroendocrine tumours: practical use Volume 24, supplement 3, Novembre 2017


  • Figure 1
  • Figure 2
  • Figure 3
  • Figure 4
  • Figure 5
  • Figure 6
  • Figure 7


1 Hôpital Beaujon,
service de gastroentérologie et pancréatologie,
100 Boulevard du Général Leclerc,
92110 Clichy, France
2 Université Paris VII,
Clichy, France
* Tirés à part

Everolimus inhibits mTOR, a key actor of cell metabolism, proliferation, survival and tumour spread. Sunitinib inhibits tyrosine-kinase receptors involved in neoangiogenesis and tumour survival and growth. They are indicated in the treatment of progressive and metastatic well-differentiated pancreatic (and intestinal for everolimus) neuroendocrine tumours. Any association with inhibitors or inductors of cytochrome P450-3A4 must be avoided, or with dose adaptation. Everolimus and sunitinib have specific side effects. Generally speaking, the occurrence of mild or severe adverse events imply to reduce the drug dose by 25 to 50% or to stop the targeted therapy, respectively. Everolimus-related most frequent adverse events include stomatitis (64%), skin rash (38%), diarrhoea (33%) and asthenia (31%). Severe side effects can occur in up to 46% of patients. Everolimus can also induce hyperglycaemia and hypercholesterolemia that must be managed. Pneumonitis can occur in up to 17% of patients and can be severe and life-threatening in 2 to 8 % of patients. Sunitinib-related most frequent adverse events include diarrhoea (59%), nausea (4%), asthenia (34%), neutropenia (29%) and high blood pressure (26%). A sunitinib-related cardiovascular toxicity is rare but potentially severe. Overall, the choice between these two targeted therapies must depend on patient individual comorbidities and the expected tolerance profile. Most toxicities are manageable easily, although patient education is primordial to optimize observance and improve quality of life.